drugset / Trial / NCT00314951

Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018)

NCT00314951

Phase 3 Completed 629 enrolled Optimer Pharmaceuticals LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a comparative study to investigate the safety and efficacy of fidaxomicin versus vancomycin in subjects with Clostridium difficile-Associated Diarrhea (CDAD).

Timeline

Start
2006-05-02
Primary completion
2008-07-23
Completion
2008-08-21

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Fidaxomicin Other / unclassified 200 mg Oral
Comparator Vancomycin Other / unclassified 125 mg Oral